The sector was doing fine yesterday until Icahn dumped on the market and everything got caught in the crossfire. This morning they are doing fine again, so it seems that as long as there is not a larger market selloff biotechs might just get time to catch their footing. Of course, it is still an […]
August 12- EOD
It looks like we are setting up to have a week of data releases with VICL today and perhaps both GTXI and MNKD later this week. It should generate some interest but none of these will likely affect biotech sentiment writ large, so they should remain stock specific stories. That being said it looks like […]
VICL – Quick take on Vical’s Allovectin failure
(With Patrick Crutcher) Today Vical (NASDAQ: VICL) reported top-line data from a Phase III trial of Allovectin-7 (A7) in patients with advanced melanoma. As we predicted in this article, the trial failed. A7 not only didn’t meet the survival endpoint, but it also missed the primary endpoint of durable response rate. Shares of Vical fell […]
VICL – Bear take on Allovectin-7
with Patrick Crutcher Vical (NASDAQ: VICL) is approaching the release of top-line data from a Phase III clinical trial of Allovectin-7 (A7) in patients with metastatic melanoma. According to the company’s last earnings call, it’s slated to occur sometime during the third quarter of this year. A7, also known as velimogene aliplasmid, is a DNA […]
Thursday at the JP Morgan Healthcare Conference
With the JP Morgan Healthcare Conference wrapped up, I wanted to highlight some notes from the Thursday session. I tried to keep them as concise as possible. We will say that we did see a lot of material that will keep up us busy for the year. You can find the webcasts to any of […]
Trade Ideas for some upcoming catalysts
We wanted to throw out some trading ideas for some stocks that we are following, but may not necessarily get full write-ups on in time. Ideally, we will have research pieces on some of the companies below in the near future. – On Thursday January 26th, Celgene(NASDAQ:CELG) will be reporting earnings and financial guidance for […]
